Dezima CETP inhibitor meets endpoint in dyslipidemia trial
Dezima Pharma B.V. (Naarden, the Netherlands) said TA-8995 (DEZ-001) alone or in combination with statin therapy met the primary endpoint vs. placebo in the 364-patient Phase IIb TULIP trial to treat dyslipidemia. The primary endpoint was a composite of the change from baseline in LDL-C and HDL-C at week 12.
ZMapp reverses advanced Ebola in monkeys
In a primate study, ZMapp from Mapp Biopharmaceutical Inc. (San Diego, Calif.) reversed 100% of advanced Ebola cases. A research group led by Gary Kobinger of the University of Manitoba that included Mapp CEO Larry Zeitlin published a paper in Nature showing all 18 rhesus monkeys survived when treated with ZMapp up to five days post infection, with severe symptoms reversed.
UTHR soars on patent win
United Therapeutics Corp. (NASDAQ:UTHR) gained $26.14 (29%) to $117.83 on Friday after the U.S. District Court for the District of New Jersey ruled that Sandoz's ANDA for generic intravenous treprostinil will infringe United Therapeutics' U.S. Patent No. 6,765,117.
Titan proposes to raise up to $12 million
Titan Pharmaceuticals Inc. (OTCBB:TTNP) proposed to raise up to $12 million through the sale of units in a follow-on underwritten by Roth Capital Partners. Each unit comprises a share and a warrant to purchase a share.
Orexo raises $50.6 million
Orexo AB (SSE:ORX; OTCQX:ORXOY) raised SEK346.5 million ($50.6 million) through the sale of 2.5 million shares at SEK139 in a private placement. The company sold 1.1 million treasury shares and issued 1.4 million new shares. Danske Bank is the sole lead manager and bookrunner. Orexo's Zubsolv buprenorphine/naloxone, a sublingual tablet formulation of buprenorphine and naloxone, is marketed in the U.S. to treat opioid dependence.
POLITICS & POLICY
White House calls for labs to check inventories
In a memorandum, the White House said all federally funded labs working with infectious agents must take "immediate and longer-term steps" to enhance biosafety and biosecurity, including taking an inventory of infectious samples and reviewing safety and security protocols. The memo was sent to federal agencies earlier this month but made publicly available on Thursday.
BioCentury Extra will not publish on Monday, Sept. 1, in observance of the Labor Day holiday in the U.S. Postings of BioCentury Extra will resume on Tuesday, Sept. 2.